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Abstract
Introduction The number of lymph nodes found to be involved
in an axillary dissection is among the most powerful prognostic
factors in breast cancer, but it is confounded by the number of
lymph nodes that have been examined. We investigate an idea
that has surfaced recently in the literature (since 1999), namely
that the proportion of node-positive lymph nodes (or a function
thereof) is a much better predictor of survival than the number of
excised and node-positive lymph nodes, alone or together.
Methods The data were abstracted from 83,686 cases
registered in the Surveillance, Epidemiology, and End Results
(SEER) program of women diagnosed with nonmetastatic T1–
T2 primary breast carcinoma between 1988 and 1997, in whom
axillary node dissection was performed. The end-point was
death from breast cancer. Cox models based on different
expressions of nodal involvement were compared using the
Nagelkerke R2 index (R2
N). Ratios were modeled as percentage
and as log odds of involved nodes. Log odds were estimated in
a way that avoids singularities (zero values) by using the
empirical logistic transform.
Results In node-negative cases both the number of nodes
excised and the log odds were significant, with hazard ratios of
0.991 (95% confidence interval 0.986–0.997) and 1.150
(1.058–1.249), respectively, but without improving R2
N. In
node-positive cases the hazard ratios were 1.003–1.088 for the
number of involved nodes, 0.966–1.005 for the number of
excised nodes, 1.015–1.017 for the percentage, and 1.344–
1.381 for the log odds. R2
N improved from 0.067 (no nodal
covariate) to 0.102 (models based on counts only) and to 0.108
(models based on ratios).
Discussion Ratios are simple optimal predictors, in that they
provide at least the same prognostic value as the more
traditional staging based on counting of involved nodes, without
replacing them with a needlessly complicated alternative. They
can be viewed as a per patient standardization in which the
number of involved nodes is standardized to the number of
nodes excised. In an extension to the study, ratios were
validated in a comparison with categorized staging measures
using blinded data from the San Jose–Monterey cancer registry.
A ratio based prognostic index was also derived. It improved the
Nottingham Prognostic Index without compromising on
simplicity.
Keywords: axillary lymph node ratio, breast neoplasm, functional form, loco-regional, log odds, nodal ratio, Nottingham Prognostic Index, predictive 
utility, prognostic factors, proportional hazards, proportion based, ratio-based prognostic index, SEER program, staging, survival
Introduction
Breast cancer is the most common neoplasm in women.
Nodal status as determined by pathologic examination of
lymph nodes has repeatedly been shown to be the single
most important predictor of survival in breast cancer [1].
The absolute number of pathologically involved nodes has
also been shown to be an important prognostic factor in
breast cancer survival [2-6]. The extent of lymph node
L = empirical logistic transform (estimated log odds); nn = number of axillary lymph nodes free from tumor involvement; np = number of pathologically 
involved axillary lymph nodes; nx = number of axillary lymph nodes examined (excised); R2
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involvement is incorporated into prognostic indices such as
the Nottingham Prognostic Index [7-9] (see Additional files
1,2,3,4,5,6). Old lymph node stage measures categorized
cases according to whether they had none, one to three, or
four or more involved nodes, and recently according to
more detailed subdivisions [10,11] (see Additional files
2,3,4,5 and 7).
However, several authors have noted the inherent con-
founding by the number of excised nodes [12,13]. To
address the variability of nodal examination, an intuitive
approach is to use the proportion or the percentage of
involved nodes, as was suggested by Rostgaard and cow-
orkers [14]. The proportion can immediately be derived
from pathology reports that clearly state the total number of
lymph nodes examined and the total number of involved
nodes [1,15]. The proportion has received increasing
attention in the literature, providing a reference base on
which its clinical relevance may be discussed [13,14,16-
27].
In this report the modeling utility of the proportion of
involved nodes is compared with the absolute numbers of
involved nodes and of examined nodes. There is a one-to-
one correspondence between proportion and ratio
between involved and uninvolved nodes. A previous study
hinted at an apparent linear relationship with survival
between involved and uninvolved nodes (Fig. 1) [28], and
therefore this report also examines the utility of expressing
ratios as odds instead of proportions.
The absolute numbers considered in the study were the
number of nodes examined (excised; nx), the number of
involved nodes (np), and the number of uninvolved nodes
(nn).
Methods
The SEER (Surveillance, Epidemiology, and End Results)
program of the USA [29] provides extensive cancer inci-
dence data from 11 population-based registries. The data
used in the present study were extracted from nine of those
registries: San Francisco-Oakland, Connecticut, Metropol-
itan Detroit, Hawaii, Iowa, New Mexico, Seattle (Puget
Sound), Utah, and Metropolitan Atlanta.
Selected patients were women without a previous history
of cancer who presented with a noninflammatory invasive
breast carcinoma, which was histologically confirmed and
diagnosed between 1988 and 1997, with specified tumor
size no larger than 50 mm (T1 and T2), strictly confined to
breasts without distant metastasis, and in which curative
surgery and axillary lymph node dissection were performed
with removal of at least one node. Cases with involvement
of skin, hypodermis or pectoral muscles, or with deep fixa-
tion were excluded. Patients who had undergone subcuta-
neous mastectomy, radical mastectomy, or preoperative or
intraoperative radiotherapy were excluded. Data on sys-
temic treatment were not available and therefore could not
be taken into account. Certain records were rejected
because of data quality concerns: uncertain sequence of
treatment, nonhospital based data records, month of diag-
nosis unknown, or race unknown. Examination of outliers
(scarce and extreme values) resulted in further exclusion of
cases with more than 50 nodes examined, '0 months' of fol-
low up, and age at diagnosis under 25 years or older than
95 years.
The follow-up cut-off date was 31 December 1999. The
survival end event was defined as death from breast
cancer.
The proportions of involved nodes were expressed as per-
centages ([np/nx] × 100%). The log odds of nodal involve-
ment were computed using the empirical logistic transform:
L = Loge([np + 0.5]/ [nn + 0.5]) [30]. The transform, also
called the sample logit, avoids singularities caused by null
observations, and is the least biased estimator of the true
log odds [31]. (Note that, with hindsight, Fig. 1 shows a
logarithmic relationship.) Unadjusted mortality (the number
of patients who died divided by the number of patients at
Figure 1
Joint effect of the numbers of involved nodes (npos) and uninvolved  nodes (nneg) on survival in T1–T2 breast cancer Joint effect of the numbers of involved nodes (npos) and uninvolved 
nodes (nneg) on survival in T1–T2 breast cancer. Part of the contour 
plot was partially filled at the corners by padding. The pattern of iso-
probability contours radiating from the origin suggests that similar ratios 
of involved/uninvolved nodes were associated with similar Kaplan–
Meier survival estimates (for example. 8 npos/10 nneg has approxi-
mately the same 75% [contour line 0.75] 5-year survival chance as 4 
npos/5 nneg). Reproduced with permission from Vin-Hung and cowork-
ers [28]. Colors were omitted in the original publication.Available online http://breast-cancer-research.com/content/6/6/R680
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risk) as a function of the ratios was used for descriptive
purposes.
The utilities of the percentage and log odds were evaluated
in different multivariate Cox proportional hazards models
[32]. The numbers np and nx, the percentage (np/nx) ×
100%, and the L transform were entered as quantitative
continuous variables in different combinations. The corre-
sponding hazard ratios were each time computed within a
Cox model that included tumor size, age at diagnosis, and
year of diagnosis modeled as quantitative continuous vari-
ables; and the registry area, race, marital status, tumor
topography, histologic type and grade, estrogen and pro-
gesterone receptor status, type of primary surgery, and
administration of postoperative radiotherapy modeled as
qualitative variables. The qualitative variables were con-
verted or expanded as needed into dummy variables to
allow binary coding ('married' versus 'not married', 'high
grade' versus 'not high grade', for example, and so on). A
first order interaction between type of surgery and postop-
erative radiotherapy was included for consistency with a
previous analysis [33]. The models were computed in all
cases irrespective of nodal status, and then as a function of
positive or negative nodal status. The functional forms were
Table 1
Distribution of the percentages of involved nodes and corresponding unadjusted mortality
Percentage of involved nodes 
(np/nx [%])
Number of patients at 
risk
All-cause mortality 
(%)
Breast cancer mortality 
(%)
Non-breast-cancer mortality 
(%)
0 58070 15.9 5.2 10.7
1–10 8695 21.6 11.7 9.9
11–20 6350 26.3 15.7 10.6
21–30 3003 30.8 19.9 10.9
32–40 2055 33.1 22.7 10.4
41–50 1487 41.0 29.6 11.4
51–60 889 37.8 28.2 9.6
61–70 719 47.0 33.7 13.4
71–80 717 50.3 40.3 10.0
81–90 658 52.6 40.4 12.2
91–100 1043 58.6 45.2 13.4
np, number of pathologically involved axillary lymph nodes; nx, number of axillary lymph nodes examined (excised).
Table 2
Distribution of the estimated log odds of nodal involvement, and corresponding unadjusted mortality
L All patients Node-negative patients Node-positive patients
Number of 
patients at risk
Breast cancer 
mortality
Non-breast-
cancer mortality
Number of 
patients at risk
Breast cancer 
mortality
Non-breast-
cancer mortality
Number of 
patients at risk
Breast cancer 
mortality
Non-breast-
cancer mortality
L ≤ -4 3053 5.4 9.2 3053 5.4 9.2 0
-4 < L ≤ -3 44695 5.3 10.2 44503 5.2 10.2 192 13.5 7.8
-3 < L ≤ -2 17619 8.0 11.5 10187 5.4 12.8 7432 11.7 9.7
-2 < L ≤ -1 9173 15.4 10.9 327 4.0 19.3 8846 15.8 10.6
-1 < L ≤ 0 5120 24.0 11.0 0 5120 24.0 11.0
0 < L ≤ 1 1943 31.9 11.3 0 1943 31.9 11.3
1 < L ≤ 2 1113 40.3 11.1 0 1113 40.3 11.1
2 < L ≤ 3 536 44.4 13.8 0 536 44.4 13.8
3 < L ≤ 4 376 47.6 13.0 0 376 47.6 13.0
4 < L 58 56.9 10.3 0 58 56.9 10.3
L = empirical logistic transform (estimated log odds).Breast Cancer Research    Vol 6 No 6    Vinh-Hung et al.
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assessed using the generalized additive model procedure
[34].
The Nagelkerke R2 index (R2
N) was used to score the differ-
ent Cox models [35]. R2 represents the proportion of varia-
tion explained by covariates in regression models [35-37].
R2
N divides R2 by its maximum attainable value to scale it to
within the range 0–1. R2
N is close to 1 for a perfectly pre-
dictive model, and close to 0 for a model that does not dis-
criminate between short and long survival times.
Statistical analyses were performed using Splus (Insightful
Corporation, Seattle, WA, USA) statistical software.
Results
In the 2002 SEER release [29], 188,410 women were
diagnosed with breast tumors from 1988 to 1997, of whom
132,457 had a hospital based histopathologic diagnosis of
unilateral invasive carcinoma. A total of 83,686 cases
matched the selection criteria; 58,070 were node-negative
and 25,616 node-positive. The median follow-up time was
73 months (range 1–143 months) for patients still alive at
the follow-up cut-off date (31 December 1999). Character-
istics of the patients were presented elsewhere [33].
Except for some additional cases due to updated registra-
tion minus the exclusion of outliers resulting in 90 fewer
cases, there were no noticeable differences in the distribu-
tion of the characteristics.
The median number of nodes examined was 15 (range 1–
50, mean ± standard deviation 15.4 ± 6.5). Among the
node-positive patients, the median number of involved
nodes was 2 (1–46, 4.1 ± 4.8).
Table 1 shows the distribution of the percentages of
involved nodes. Figure 2 is a plot of the corresponding
breast cancer mortality, which appears to increase linearly
with the np/nx percentage.
Table 2 shows the distribution of the log odds for nodal
involvement. Figure 3 plots the corresponding breast can-
cer mortality. There is an initial, almost flat segment for val-
ues of L ≤ -3, which is followed by a steeply sloping upward
segment. The initial flat segment corresponds mostly to
node-negative cases. The sloping upward segment corre-
sponds to node-positive cases, with more positive L values
indicating more involved nodes and/or fewer uninvolved
nodes. There is an overlap between node-negative and
node-positive cases for L values between -3.5 and -1.
In multivariate analyses, np and nx exhibited marked nonlin-
earity and widely diverging confidence intervals (Fig.
4a,4b). The linearity improved for the percentage (np/nx) ×
100% and the L transform, which also showed more homo-
geneously distributed confidence intervals (Fig. 4c,4d).
The upper section of Table 3 shows a comparison between
proportional hazards models that included different combi-
nations of np, nx, np/nx, and L for all patients, irrespective
of nodal status. Based on R2
N, the best predictive covariate
was L (model 6), with a small improvement contributed by
nx (model 10). In the model with nx alone (model 3), nx was
statistically significant but its contribution to global model
fit appeared negligible because the R2
N did not change
from the baseline 0.069 (model 1). The contribution of np
alone was substantial, with a change of R2
N from baseline
0.069 to 0.093 (model 2). However, adding np and/or nx
onto L or onto np/nx provided no improvement, except in
the already mentioned model 10.
The middle section of Table 3 shows multivariate analysis
performed for node-positive cases only. Models based on
separately expressed numbers provided the lowest R2
N
(models 2–4). The largest R2
N values were all observed in
models incorporating L or np/nx (models 5–11). The sim-
plest model appeared to be based on np/nx alone (model
5; R2
N = 0.108). A small improvement was contributed by
np (model 7; R2
N = 0.109).
Figure 2
Unadjusted breast-cancer mortality as a function of the percentage of  involved nodes in T1–T2 breast cancer based on the SEER (Surveil- lance, Epidemiology, and End Results) program data Unadjusted breast-cancer mortality as a function of the percentage of 
involved nodes in T1–T2 breast cancer based on the SEER (Surveil-
lance, Epidemiology, and End Results) program data. Dot size com-
puted as a step function of the number of patients at risk: smallest dots 
1–20 patients and the largest dots >200 patients. The straight line 
highlights the trend but should not be interpreted as the basis for 
extrapolation.Available online http://breast-cancer-research.com/content/6/6/R680
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The lower section of Table 3 shows the analysis performed
for node-negative cases only. Because np, by definition,
equals 0, there are only four models. They show that nx
(model 3) and L (model 6) are statistically significant, but
these variables either alone or in combination did not
improve the index R2
N.
The multivariate computations were also performed by con-
sidering death from any cause as the end-point. There were
no notable discrepancies.
Discussion
Although many data were evaluated in the present study,
there are weaknesses. The data are heterogeneous. His-
topathologic characteristics such as grade could not be
verified. Neoadjuvant systemic treatment might have modi-
fied the yield of nodes [38]. Important information such as
how patients were selected for any particular treatment is
missing. Undocumented comorbidity might have affected
the extent of nodal dissection. An imbalance in the delivery
of chemotherapy or hormone therapy could have affected
the distribution of deaths. For all of these reasons, the
present results should be considered explorative and must
be validated independently.
Since about 1999 a growing number of studies have inves-
tigated nodal ratios. In the studies that compared the num-
bers of involved nodes with ratios in multivariate models,
the majority found that ratios were better than numbers as
prognostic indicators [13,16,18,19,24,26]. Ratios
(expressed as percentages or log odds) have a better prog-
nostic impact than do isolated numbers and, unlike num-
bers, they are not associated with inconsistent findings.
Part of the explanation might be that a ratio can be inter-
preted as a form of standardization in which the number of
involved nodes found in a patient is standardized to the
number of nodes examined in that same patient [20]. It is
noteworthy that the hazard ratios for np/nx were almost
unaffected by the model (column np/nx [%] in Table 3),
Figure 3
Unadjusted breast cancer mortality as a function of the estimated log  odds of nodal involvement in T1–T2 breast cancer Unadjusted breast cancer mortality as a function of the estimated log 
odds of nodal involvement in T1–T2 breast cancer. Red dots are node-
negative patients, and blue are node-positive patients. The smallest 
dots represent 1–20 patients and the largest dots represent >200 
patients. The straight lines highlight the different slopes but should not 
be interpreted as the basis for extrapolation (they would extrapolate to 
<0% or >100% mortalities).
Figure 4
Adjusted breast cancer mortality in T1–T2 node-positive breast cancer  as a function of (a) number of nodes examined, (b) number of involved  nodes, (c) percentage of involved nodes, and (d) log odds of involved  nodes Adjusted breast cancer mortality in T1–T2 node-positive breast cancer 
as a function of (a) number of nodes examined, (b) number of involved 
nodes, (c) percentage of involved nodes, and (d) log odds of involved 
nodes. Dotted lines indicate the 95% confidence interval. Plots are 
based on multivariate models that included all non-nodal covariates 
listed in the Methods section and a single nodal covariate. Analysis of 
cases pooled irrespective of nodal status revealed a more marked non-
linearity in plot c between 0% and 20% involved nodes. Otherwise, dif-
ferent combinations of nodal covariates gave similar plots.Breast Cancer Research    Vol 6 No 6    Vinh-Hung et al.
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whereas the hazard ratios for np and/or nx exhibited more
variability (columns np and nx in Table 3).
As a prognostic factor, np/nx appears the most convenient.
Figure 2 shows that, for node-positive cases presenting
with 0–10% involved nodes, the crude breast cancer
mortality risk for an average follow up of 6 years is about
5%, and with 90–100% involved nodes the mortality is
about 45%. For any intermediate value for the percentage
of node involvement, the mortality risk is easily interpolated.
Table 3
Comparison of models
Patients studied R2
N Hazard ratios (95% confidence interval)
np nx np/nx (%) L
All cases
1: no nodal variables 0.069
2: np 0.093 1.093 (1.090–1.097)
3: nx 0.069 0.998 (0.995–1.001)
4: np, nx 0.096 1.112 (1.108–1.116) 0.970 (0.966–0.974)
5: np/nx (%) 0.104 1.023 (1.022–1.024)
6: L 0.108 1.459 (1.442–1.477)
7: np, np/nx (%) 0.104 1.010 (1.004–1.017) 1.021 (1.020–1.023)
8: nx, np/nx (%) 0.104 1.002 (0.999–1.005) 1.023 (1.022–1.024)
9: np, L 0.108 0.998 (0.992–1.005) 1.466 (1.435–1.497)
10: nx, L 0.109 1.009 (1.006–1.013) 1.462 (1.445–1.479)
11: np, nx, np/nx (%) 0.104 1.013 (1.004–1.022) 0.998 (0.994–1.002) 1.021 (1.019–1.022)
12: np, nx, L 0.109 0.967 (0.957–0.976) 1.021 (1.017–1.026) . 1.599 (1.554–1.646)
Node-positive patients
1: no nodal variables 0.067
2: np 0.095 1.066 (1.062–1.071)
3: nx 0.067 0.996 (0.992–1.000)
4: np, nx 0.102 1.088 (1.083–1.093) 0.966 (0.961–0.971)
5: np/nx (%) 0.108 1.017 (1.016–1.018)
6: L 0.108 1.379 (1.355–1.403)
7: np, np/nx (%) 0.109 1.013 (1.006–1.020) 1.015 (1.014–1.017)
8: nx, np/nx (%) 0.108 1.005 (1.001–1.009) 1.017 (1.016–1.018)
9: np, L 0.108 1.008 (1.001–1.016) 1.344 (1.306–1.384)
10: nx, L 0.108 1.005 (1.001–1.009) 1.381 (1.357–1.405)
11: np, nx, np/nx (%) 0.109 1.016 (1.005–1.028) 0.998 (0.991–1.004) 1.015 (1.013–1.017)
12: np, nx, L 0.108 1.003 (0.990–1.017) 1.003 (0.996–1.010) 1.366 (1.304–1.431)
Node-negative patients
1: no nodal variables 0.045 NA
3: nx 0.045 NA 0.991 (0.986–0.997)
6: L 0.045 NA 1.150 (1.058–1.249)
10: nx, L 0.045 NA 1.001 (0.984–1.019) 1.169 (0.902–1.514)
Shown are all nodal status combined, and node-positive patients and node-negative patients separately. A hazard ratio >1 indicates increased risk 
for death from breast cancer. All models are multivariate, adjusting for the effect of covariates listed in the Methods section: tumor size, age at 
diagnosis, year of diagnosis, registry area, race, marital status, tumor topography, histologic type and grade, estrogen and progesterone receptor 
status, type of primary surgery, and administration of postoperative radiotherapy. NA, not applicable; np, number of involved nodes; nx, number of 
nodes examined; np/nx (%), percentage of nodes involved; L, log-odds of node involvement; R2
N, Nagelkerke R2 index of global model fit (0 = lack 
of fit, 1 = perfect fit).Available online http://breast-cancer-research.com/content/6/6/R680
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The estimated log odds L provided results very similar to
those with np/nx. Overall, L improves on np/nx when all
cases are considered together (column L in Table 3). The
log odds appears useful for integrating node-negative and
node-positive cases while avoiding more complex mode-
ling, which we performed previously [39]. However, there is
a range of L values in which node-negative and node-posi-
tive cases overlap (Table 2, Figure 3). In an analysis of all
cases pooled, the overlap might blur the prognostic
difference between node-negative status based on a very
small number of excised nodes, and node-positive status
based on a large number of excised nodes but with few
involved nodes. The literature on the log odds of node
involvement is scarce, and the utility of the L transform
needs independent confirmation.
The present findings indicate that the favorable survival
attributed to higher numbers of nodes removed, as sug-
gested by Krag and Single [40], might be due to different
model specifications. The number of patients is huge and
statistical significance can easily be demonstrated but
without necessarily implying any major clinical impact.
Undoubtedly, the uncertainty about node negativity
increases when nx (the number of excised nodes) is small.
However, the predictive utility attributable to nx is
exceedingly small (Table 3, lower section). This dissocia-
tion between statistical significance and predictive utility
appears counterintuitive. Nevertheless, it is in keeping with
findings from Fisher and coworkers [41], who noted that
prognosis was unaffected by the number of excised nodes
when nodal status was reported to be negative. This is also
supported by a recent report based on 3800 patients [42]
in which the number of excised nodes was predictive of the
risk for recurrence in node-positive but not in node-negative
patients.
Sentinel node biopsy has gained wide acceptance since
1997 and it is used to determine the need for axillary
dissection [43]. Because our selection of patients was
from 1988 until 1997, it is unlikely that sentinel nodes could
have represented any substantial part of the present study.
The prognostic impact of one involved node in patients who
had one node removed in this study cannot be extrapolated
to the patient found with one involved node in a sentinel
node procedure. However, in the prediction of nonsentinel
node involvement when one or more sentinel nodes are
found to be involved, Cserni and coworkers [44] reported
that the number of sentinel nodes and the percentage of
positive sentinel nodes were jointly significant predictors. A
closely related finding that also highlights the predictive
role of ratios was reported in a recent Australian study [45],
in which the prediction model was determined by patient
age, by the number of sentinel nodes, and by the proportion
of involved sentinel nodes.
Conclusion
We found the percentage of involved nodes to be the most
directly useful indicator of nodal involvement, but this is lim-
ited to node-positive cases. The log odds of nodal involve-
ment performed equally well in node-positive and node-
negative patients. The log odds might provide a unified
approach to the modeling of nodal involvement. The
present results and the growing literature argue that ratios
should be considered in the staging of axillary dissection.
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